Status:
COMPLETED
Study of Ambrisentan in Participants With Pulmonary Hypertension
Lead Sponsor:
Gilead Sciences
Conditions:
Pulmonary Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The primary objective of this study is to monitor the long-term safety of ambrisentan in adult participants with pulmonary hypertension. The available ambrisentan doses for this study are 2.5, 5, or 1...
Eligibility Criteria
Inclusion
- Key
- Men and women with pulmonary hypertension who are discontinuing a clinical study of ambrisentan due to study closure by the sponsor. Eligible participants are those participating in countries where ambrisentan is not yet commercially available. Participants participating in countries where ambrisentan is commercially available may be eligible if they do not qualify for treatment per the current prescribing information of that country.
- Key
Exclusion
- Participants who have discontinued an ambrisentan clinical study for any other reason than sponsor-initiated study closure are not eligible.
- Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
November 17 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 11 2019
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT00777920
Start Date
November 17 2008
End Date
September 11 2019
Last Update
September 30 2020
Active Locations (46)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
2
Arizona Pulmonary Specialists
Phoenix, Arizona, United States, 85013
3
University of Colorado Health Science Center
Aurora, Colorado, United States, 80045
4
University of Connecticut Health Center
Farmington, Connecticut, United States, 06030